Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28293552 | 0.82 | TRPV4 (0.69) | TRPV4NR3C1PGRNFE2L2SLC22A12 | |
| SCHEMBL31399726 | 0.80 | TRPV4 (0.67) | TRPV4NR3C1PGRGRM4 | |
| SCHEMBL30504923 | 0.77 | TRPV4 (0.63) | TRPV4NFE2L2SLC22A12CA1CA2 | |
| SCHEMBL7867107 | 0.77 | TRPV4 (0.63) | TRPV4NFE2L2SLC22A12CA1CA2 | |
| SCHEMBL2646025 | 0.73 | TRPV4 (0.57) | TRPV4NR3C1PGRGRM4RXRA | |
| SCHEMBL31348081 | 0.73 | TRPV4 (0.57) | TRPV4NFE2L2GRM4RXRAGRIN1 | |
| SCHEMBL363458 | 0.73 | TRPV4 (0.57) | TRPV4NFE2L2GRM4RXRAGRIN1 | |
| SCHEMBL21046774 | 0.72 | TRPV4 (0.56) | TRPV4SLC22A12RXRAGRIN1GRIN2B | |
| SCHEMBL30989845 | 0.72 | TRPV4 (0.56) | TRPV4SLC22A12 | |
| SCHEMBL1610883 | 0.72 | TRPV4 (0.56) | TRPV4SLC22A12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023159322-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-08-31 | — | — | WO | disclosed |
| US-11260049-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-03-01 | — | — | US | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| EP-3515887-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-07-07 | — | — | EP | disclosed |
| EP-3515888-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-20200261411-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| US-10588891-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11260049-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885NR3C1 3622/4885PGR 2342/4885 |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885NR3C1 3622/4885PGR 2342/4885 |
| US-10588891-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885NR3C1 3622/4885PGR 2342/4885 |
| US-11229623-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885NR3C1 3622/4885PGR 2342/4885 |
| US-20200261411-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885NR3C1 3622/4885PGR 2342/4885 |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885NR3C1 3622/4885PGR 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.